Bryan Garnier - FIELMANN (FIEG.DE) FIELMANN: Some air pockets but still a relatively safe choice in volatile conditions | BUY | EUR76 VS. EUR78 (+19%)

Report

Bryan Garnier

Cedric Rossi

FIELMANN: Some air pockets but still a relatively safe choice in volatile conditions | BUY | EUR76 VS. EUR78 (+19%)

FIELMANN - BUY | EUR76 VS. EUR78 (+19%)
Some air pockets but still a relatively safe choice in volatile conditions

Lingering Covid impact on Q1 numbers
Top line trends are relatively resilient vs. peers
2021 outlook: FIE considers two scenarios for overcoming Covid crisis
FIE enters the Czech eyewear market this summer
Buy rating reiterated, FV nudged down to EUR76

30/04/2021 4 EN

Underlying

FIELMANN

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cedric Rossi

Other Reports on these Companies

Bryan Garnier

FIELMANN: Good Q1 results but FY22 sales outlook tinted with a touch of cautiousness | BUY | EUR74

FIELMANN - BUY | EUR74 Good Q1 results but FY22 sales outlook tinted with a touch of cautiousness FY21 results: PBT miss on an aggressive CS estimate but fairly in line with FIE’s guidance Q1 2022 results: off to a good start FY22 sales outlook a bit more prudent given a challenging environment in Central & Eastern Europe

April 28, 2022 April 28, 2022 1 EN

Bryan Garnier

FIELMANN - BUY | EUR74 vs. EUR76 Mixed bag of FY21 results but upbeat FY22 sales outlook reiterated

FY21 sales broadly in line with CS expectations Reasons for this FY21 PBT miss Ambitious FY22 sales guidance confirmed

February 25, 2022 February 25, 2022 1 EN

Bryan Garnier

FIELMANN: Good surprises planned for next year? | BUY | EUR76(+25%)

FIELMANN - BUY | EUR76(+25%) Good surprises planned for next year? Q3: customers are back to physical stores International becoming an increasingly key contributor to sales growth FY21 sales outlook reiterated, hence minor forecast adjustments… … but significant upside potential on FY22 estimates as FIE guides on DD sales growth!

November 12, 2021 November 12, 2021 5 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

April 25, 2025 April 25, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

April 25, 2025 April 25, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

April 25, 2025 April 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

FIELMANN: Some air pockets but still a relatively safe choice in volatile conditions | BUY | EUR76 VS. EUR78 (+19%)

FIELMANN: Good Q1 results but FY22 sales outlook tinted with a touch of cautiousness | BUY | EUR74

FIELMANN - BUY | EUR74 vs. EUR76 Mixed bag of FY21 results but upbeat FY22 sales outlook reiterated

FIELMANN: Good surprises planned for next year? | BUY | EUR76(+25%)

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe